Scope Fluidics gets EIB loan for infection diagnostics

Scope Fluidics AS said it will use the financing to push the development of its microfluidic plattform that allows microbial growth analysis of diluted precultures within 60 minutes of time and its PCR|One platform for pathogen detection at the point of care. Thanks to a €1.93mg Horizon 2020 grant for the Bacteromics project, Scope Fluidics has been able to develop a cartridge-based system and analyser that allows simultanous antibiotics susceptibility tests of bacterial pathogens. Furthermore the company’s POC PCR platform allows tdetection of viral or bacterial pathogens within 15 minutes of time, including SARS-COV-2.

By sustaining the company’s clinical trials that will allow the commercial launch of the system, the EIB helps address a market gap in available financing options for innovative players active in developing new vaccines and drugs, innovative medical and diagnostic devices or novel research infrastructure for combatting infectious diseases (ID). The project has also the potential to foster growth in this sector and create new jobs in Poland and in the EU for highly skilled people and in the field of research and development.

The financing is the the first project in Poland funded by the Infectious Diseases Finance Facility (IDFF) for a total amount of €372m. “The Scope Fluidics team has created a modern PCR|ONE system that detects dangerous bacteria and viruses in a breakthrough time of 15 minutes. Our recent efforts focused on the rapid detection of the Covid-19 virus have given the PCR|ONE project an additional importance and business dimension - in line with the global effort to combat the pandemic," said Piotr Garstecki, CEO of Scope Fluidics.“

End of August the company took part as a presenting company in the 4th AMR conference which took place digitally this year. More than 450 attendees joined this stakeholder event. Current trends and developments for diagnostics developers were discussed alongside several other topics relevant for businesses active in the global fight against antimicrobial resistance. The five-day digital conference particularly focused on market conditions and financing. SMEs and global partners urged for more pull incentives.